Literature DB >> 32382935

Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients.

Roberta Bruhn1,2, Matthew S Karafin3, Joan F Hilton2, Zhanna Kaidarova1, Bryan R Spencer4, Lirong Qu5, Edward L Snyder6, Rebecca Olin2, Edward L Murphy1,2, Elizabeth St Lezin7,8.   

Abstract

PURPOSE: Outpatients with hematologic disease often receive red cell transfusion to treat anemia and fatigue. The effect of transfusion on fatigue-related quality of life and how well this effect is sustained has not been quantified. The study aim was to describe the early and sustained impact over 4 weeks of red cells on patient-reported fatigue in outpatients age ≥ 50 receiving transfusion as routine clinical care.
METHODS: FACIT-Fatigue scale scores were measured pre-transfusion and at visits targeting 3, 7, and 28 days post-transfusion. Group-based trajectory modeling of patient fatigue scores by study day was used to identify the number of distinct trajectories (Groups), then longitudinal mixed effects modeling of fatigue scores was used to estimate group-specific mean improvements early after transfusion and between days 3 and 28 post-transfusion.
RESULTS: Four distinct fatigue score trajectory groups were identified and were found to be correlated with baseline fatigue scores (means 12, 26, 34, and 47 points). In the three groups with the lowest fatigue trajectories (indicating greater fatigue), improvements in fatigue early after transfusion achieved the established minimum clinically important difference (≥ 3 points, Group p = 0.0039). In all trajectory groups, mean fatigue levels did not change significantly between 3 and 28 days (± 1 point, Group p = 0.60).
CONCLUSION: Patient-reported fatigue varies widely among older adult outpatients with hematologic disorders. Nonetheless, trajectory modeling suggests that most anemic patients can expect a noticeable improvement in fatigue in the first few days after transfusion that generally is sustained up to 4 weeks.

Entities:  

Keywords:  Fatigue; Fatigue-related quality of life; Patient-reported outcomes; Red blood cells; Transfusion practice

Mesh:

Year:  2020        PMID: 32382935      PMCID: PMC7572478          DOI: 10.1007/s11136-020-02517-2

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  31 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Factors affecting patient-reported outcomes after red blood cell transfusion in medical patients.

Authors:  Ka Lok Luke Chan; Wai Man Vivien Mak; Yat Hung Tam; Kwok Kuen Harold Lee
Journal:  Transfusion       Date:  2017-11-13       Impact factor: 3.157

3.  Outpatient transfusions: time to study what matters to patients.

Authors:  Yulia Lin; Rena Buckstein
Journal:  Transfusion       Date:  2019-06       Impact factor: 3.157

4.  Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

Authors:  S B Yellen; D F Cella; K Webster; C Blendowski; E Kaplan
Journal:  J Pain Symptom Manage       Date:  1997-02       Impact factor: 3.612

5.  Fatigue in cancer patients compared with fatigue in the general United States population.

Authors:  David Cella; Jin-Shei Lai; Chih-Hung Chang; Amy Peterman; Mitchell Slavin
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

Review 6.  Red blood cell transfusion: a clinical practice guideline from the AABB*.

Authors:  Jeffrey L Carson; Brenda J Grossman; Steven Kleinman; Alan T Tinmouth; Marisa B Marques; Mark K Fung; John B Holcomb; Orieji Illoh; Lewis J Kaplan; Louis M Katz; Sunil V Rao; John D Roback; Aryeh Shander; Aaron A R Tobian; Robert Weinstein; Lisa Grace Swinton McLaughlin; Benjamin Djulbegovic
Journal:  Ann Intern Med       Date:  2012-07-03       Impact factor: 25.391

7.  The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials.

Authors:  D Cella; J Kallich; A McDermott; X Xu
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

8.  Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial.

Authors:  Simon J Stanworth; Sally Killick; Zoe K McQuilten; Marina Karakantza; Robert Weinkove; Heather Smethurst; Laura A Pankhurst; Renate L Hodge; Valerie Hopkins; Helen L Thomas; Alison J Deary; Jeannie Callum; Yulia Lin; Erica M Wood; Rena Buckstein; David Bowen
Journal:  Br J Haematol       Date:  2020-01-20       Impact factor: 6.998

Review 9.  Red Blood Cell Transfusion Strategies in Adult and Pediatric Patients with Malignancy.

Authors:  Nareg Roubinian; Jeffrey L Carson
Journal:  Hematol Oncol Clin North Am       Date:  2016-02-18       Impact factor: 3.722

10.  Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia.

Authors:  Tamara E Lacourt; Annemieke Kavelaars; Maro Ohanian; Nina D Shah; Samuel A Shelburne; Andrew Futreal; Dimitrios P Kontoyiannis; Cobi J Heijnen
Journal:  Oncotarget       Date:  2018-07-27
View more
  2 in total

1.  Racial differences in red blood cell transfusion in hospitalized patients with anemia.

Authors:  Micah Prochaska; Jorge Salcedo; Grace Berry; David Meltzer
Journal:  Transfusion       Date:  2022-06-03       Impact factor: 3.337

Review 2.  Management of the Older Patient with Myelodysplastic Syndrome.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  Drugs Aging       Date:  2021-08-03       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.